Review article: fructose in non-alcoholic fatty liver disease

被引:51
|
作者
Yilmaz, Y. [1 ,2 ]
机构
[1] Marmara Univ, Inst Gastroenterol, TR-34840 Istanbul, Turkey
[2] Marmara Univ, Sch Med, Dept Gastroenterol, TR-34840 Istanbul, Turkey
关键词
BROWN ADIPOSE-TISSUE; GLYCATION END-PRODUCTS; INDUCED HEPATIC STEATOSIS; SPRAGUE-DAWLEY RATS; METABOLIC SYNDROME; INSULIN-RESISTANCE; DIETARY FRUCTOSE; LIPID-ACCUMULATION; SOLUBLE RECEPTOR; BLOOD-PRESSURE;
D O I
10.1111/j.1365-2036.2012.05080.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background The role of excess fructose intake in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) has recently received increasing attention, but the pathophysiology of this relationship has been only partly elucidated. Aini To provide an overview of the potential role played by fructose in the pathogenesis of NAFLD by focusing on both indirect and direct harmful effects. Methods Experimental and clinical studies which investigated the relation of fructose with NAFLD are reviewed. Results Several factors may potentially contribute to fructose-induced NAFLD, including the induction of the metabolic syndrome, copper deficiency, bacterial translocation from the gut to the liver, the formation of advanced glycation endproducts and a direct dysmetabolic effect on liver enzymes. Conclusions Experimentally-increased fructose intake recapitulates many of the pathophysiological characteristics of the metabolic syndrome in humans, which may in turn lead to NAFLD. However, the majority of experimental studies tend to involve feeding excessively high levels of fructose (60-70% of total energy intake) which is not reflective of average human intake. Hopefully, the combination of in vivo, in vitro and genetic research will provide substantial mechanistic evidence into the role of fructose in NAFLD development and its complications.
引用
收藏
页码:1135 / 1144
页数:10
相关论文
共 50 条
  • [41] Non-alcoholic fatty liver disease
    Cua, IHY
    George, J
    HOSPITAL MEDICINE, 2005, 66 (02): : 106 - 111
  • [42] Non-alcoholic fatty liver disease
    Tuyama, Ana C.
    Chang, Charissa Y.
    JOURNAL OF DIABETES, 2012, 4 (03) : 266 - 280
  • [43] Non-alcoholic fatty Liver disease
    Calderaro, Julien
    Zafrani, Elie Serge
    ANNALES DE PATHOLOGIE, 2010, 30 (06) : 413 - 420
  • [44] Non-alcoholic fatty liver disease
    Farrell, Geoffrey C.
    Wardell, Rebecca
    Teoh, Narci
    Chitturi, Shiv
    INTERNAL MEDICINE JOURNAL, 2019, 49 (05) : 681 - 683
  • [45] Non-alcoholic fatty liver disease
    Adams, LA
    Angulo, P
    LIVER DISEASES: ADVANCES IN TREATMENT AND PREVENTION: IN HONOUR OF HANS POPPER'S 100TH BIRTHDAY, 2004, 137 : 250 - 270
  • [46] Non-Alcoholic Fatty Liver Disease
    Engin, Atilla
    OBESITY AND LIPOTOXICITY, 2017, 960 : 443 - 467
  • [47] Non-alcoholic fatty liver disease
    Brent A. Neuschwander-Tetri
    BMC Medicine, 15
  • [48] Non-alcoholic fatty liver disease
    Alba, LM
    Lindor, K
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (08) : 977 - 986
  • [49] Non-alcoholic fatty liver disease
    Sattar, Naveed
    Forrest, Ewan
    Preiss, David
    BMJ-BRITISH MEDICAL JOURNAL, 2014, 349
  • [50] Non-alcoholic fatty liver disease
    Li, Wenhao
    Alazawi, William
    CLINICAL MEDICINE, 2020, 20 (05) : 509 - 512